PANEL OF SERUM BIOMARKERS MAY PREDICT BENEFIT FROM BEVACIZUMAB (BEV) IN ADVANCED NSCLC PATIENTS

被引：0
|
作者：
Braun, Eduardo [1 ]
Fidler, Mary Jo [1 ]
Basu, Sanjib [1 ]
Gargaram, Anjali [2 ]
Walters, Kelly [2 ]
Fhied, Cristina [2 ]
Borgia, Jeffrey A. [2 ]
Bonomi, Philip D. [1 ]
机构：
[1] Rush Univ, Med Ctr, Div Oncol, Chicago, IL 60612 USA
[2] Rush Univ, Med Ctr, Div Biochem, Chicago, IL 60612 USA
来源：
JOURNAL OF THORACIC ONCOLOGY | 2012年 / 7卷 / 07期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S124 / S125
页数：2
相关论文
共 50 条
  • [31] Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients
    Passiglia, F.
    Galvano, A.
    Parra, H. Soto
    Rizzo, S.
    Listi, A.
    Mazzarisi, S.
    Perez, A.
    Castiglia, M.
    Calo, V.
    Bazan, V.
    Russo, A.
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (10) : S734 - S734
  • [32] The serum LDH level and KELIM scores are potential predictors of a benefit from bevacizumab first-line therapy for patients with advanced ovarian cancer
    Liu, Yi
    Yuan, Lin
    Lin, Zhang
    Miao, Huixian
    Meng, Huangyang
    Cheng, Wenjun
    CLINICAL & TRANSLATIONAL ONCOLOGY, 2025, 27 (01): : 340 - 350
  • [33] CEA and CYFRA 21-1 as Prognostic Biomarkers of Benefit from Nivolumab and as a Tool in Treatment Monitoring in Advanced NSCLC
    Dall'Olio, F. G.
    Abbati, F.
    Facchinetti, F.
    Gelsomino, F.
    Melotti, B.
    Massucci, M.
    Buti, S.
    Veneziani, M.
    Tiseo, M.
    Ardizzoni, A.
    JOURNAL OF THORACIC ONCOLOGY, 2019, 14 (10) : S257 - S257
  • [34] Predictive value of LDH kinetics in bevacizumab treatment and survival of patients with advanced NSCLC
    Li, Butuo
    Li, Cheng
    Guo, Meiying
    Shang, Shuheng
    Li, Xiaogang
    Xie, Peng
    Sun, Xindong
    Yu, Jinming
    Wang, Linlin
    ONCOTARGETS AND THERAPY, 2018, 11 : 6287 - 6294
  • [35] THE COMBINATION CHEMOTHERAPY OF CARBOPLATIN AND WEEKLY PACLITAXEL PLUS BEVACIZUMAB IN PATIENTS WITH ADVANCED NSCLC
    Kitaguchi, S.
    Kagawa, M.
    Yamaguchi, K.
    Watanabe, M.
    Ogawa, T.
    Furonaka, O.
    Sugahara, F.
    Egawa, H.
    ANNALS OF ONCOLOGY, 2013, 24
  • [36] Personalized ctDNA Detection to Monitor Outcome and Predict Immunotherapy Benefit in Locally Advanced and Metastatic NSCLC
    Gao, G.
    Cheng, L.
    Zhao, C.
    Li, X.
    Yao, C.
    Li, F.
    You, D.
    Zhou, C.
    JOURNAL OF THORACIC ONCOLOGY, 2022, 17 (09) : S353 - S354
  • [37] IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
    French, Pim
    Erdem-Eraslan, L.
    Kros, J. M.
    Oosterkamp, H. M.
    Walenkamp, A. M. E.
    Beerepoot, L.
    Hanse, M.
    Buter, J.
    Honkoop, A.
    van der Holt, B.
    Vernhout, R. M.
    Smitt, P. A. E. Sillevis
    Taal, W.
    van den Bent, M. J.
    NEURO-ONCOLOGY, 2014, 16
  • [38] IDENTIFICATION OF PATIENTS WITH RECURRENT GBM THAT BENEFIT FROM BEVACIZUMAB
    Eraslan, Lale Erdem
    van den Bent, Martin
    Kros, Johan
    Oosterkamp, Hendrika
    Walenkamp, Annemiek
    Beerepoot, Laurens
    Hanse, Monique
    Buter, J.
    Honkoop, Aafke
    van der Holt, Bronno
    Vernhout, R. M.
    Smitt, Peter Sillevis
    Taal, Walter
    French, Pim
    NEURO-ONCOLOGY, 2014, 16
  • [39] The Lung Immune Prognostic Index May Predict the Efficacy of Different Treatments in Patients with Advanced NSCLC: A Meta-Analysis
    Xie, Jianhua
    Zang, Yuqin
    Liu, Miaomiao
    Peng, Lili
    Zhang, Hongzhen
    ONCOLOGY RESEARCH AND TREATMENT, 2021, 44 (04) : 164 - 174
  • [40] Patients with advanced hepatocellular Carcinoma may also benefit from Lenvatinib in clinical Practice
    不详
    ONCOLOGY RESEARCH AND TREATMENT, 2022, 45 (06)
12345